Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Survivin, also known as BIRC5, is a protein that inhibits apoptosis and regulates cell division. It is highly expressed in embryonic development and most human tumors, but rarely detectable in differentiated adult tissues. Survivin is a member of the inhibitor of apoptosis (IAP) family. It plays a dual role in inhibiting programmed cell death and regulating cell division, making it a critical factor in cancer biology. It is an attractive target for anticancer therapies.
Antisense oligonucleotides bind to survivin mRNA, leading to its degradation and reduced survivin protein levels. Small molecule inhibitors directly bind to survivin and disrupt its function. Immunotherapies stimulate the immune system to target and kill cells expressing survivin.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Survivin (BIRC5).